Septerna
Develops oral GPCR drug candidates using its Native Complex Platform.
$38.91
After-hours close+0.05 (+0.13%)
At close$38.86(−3.98%)
Something off on this page? Send us feedback.
Breakdown13F · Form 4
Institutions 106.01%Insiders 13.55%
A 13F quarter can total more than the shares outstanding — sub-advisers file the same block twice, and a filer's own share count can be a quarter stale. No split is drawn from it.
Shares outstanding 45.08M · Float 18.88M · 41.9% free float
Institutions13F, as of Jun 30, 2026
166 holders · 47.78M shares · 51 new positions · 102 increased · 32 reduced · 17 closed
| Holder | Shares | % outstanding | Chg q/q | Filed |
|---|---|---|---|---|
| Ra Capital Management, L.P. | 7.00M | 15.52% | 0 | Aug 14, 2026 |
| TRV GP V, LLC | 6.22M | 13.79% | 0 | Aug 10, 2026 |
| Driehaus Capital Management LLC | 4.43M | 9.83% | +37.5K | Aug 14, 2026 |
| TRV GP Vi, LLC | 4.21M | 9.34% | 0 | Aug 10, 2026 |
| Samsara Biocapital, LLC | 3.15M | 6.99% | 0 | Aug 14, 2026 |
| Goldman Sachs Group Inc | 3.06M | 6.79% | +156.3K | Aug 14, 2026 |
| BlackRock, Inc. | 1.93M | 4.29% | +109.9K | Aug 7, 2026 |
| Siren, L.L.C. | 1.90M | 4.22% | −100.0K | Aug 13, 2026 |
Beneficial owners13D/G · 5% or more, as filed
| Holder | % of class | Shares | Form | Filed |
|---|---|---|---|---|
| Rajeev Shahincl. Peter Kolchinsky, RA Capital Management, L.P. +1 more | 15.80% | 7.00M | 13D | Nov 4, 2024 ↗ |
| Third Rock Ventures V, L.P. | 14.00% | 6.22M | 13G | May 9, 2025 ↗ |
| Driehaus Capital Management LLC | 10.46% | 4.66M | 13G | Jun 10, 2025 ↗ |
| Samsara BioCapital, L.P.incl. Samsara BioCapital GP, LLC, Srinivas Akkaraju | 6.20% | 2.77M | 13G | Nov 4, 2024 ↗ |
| BVF Partners L.P.incl. Biotechnology Value Trading Fund OS LP, BVF I GP LLC +7 more | 5.50% | 2.45M | 13G | Nov 1, 2024 ↗ |
InsidersForm 4
| Insider | Role | Shares | % outstanding | Filed |
|---|---|---|---|---|
| Third Rock Ventures V, L.P. | 10 percent owner | 8.94M | 19.84% | Aug 14, 2026 |
| Ra Capital Management, L.P. | director, 10 percent owner: | 4.78M | 10.60% | Aug 14, 2026 |
| Jeffrey Finer | director, officer: CEO and President | 826.9K | 1.83% | Apr 4, 2025 |
| Elizabeth Bhatt | officer: President and COO | 174.2K | 0.39% | Aug 13, 2026 |
| Alan Ezekowitz | director | 117.4K | 0.26% | Mar 10, 2025 |
| Uwe Klein | officer: SVP, Biological Sciences | 115.0K | 0.26% | Aug 19, 2025 |
| Daniel D. Long | officer: SVP, Drug Discovery | 96.4K | 0.21% | Aug 5, 2026 |
| Samira Shaikhly | officer: Chief People Officer | 793 | 0.00% | Jun 30, 2026 |
2 ten-percent owners hold 13.15M shares by Form 4 — the 13D/G table above shows those stakes, the figure above counts officers and directors only · 2 people have not refiled in the last 18 months (98.1K shares), so they are not in the figure above
Latest trades
| Date | Insider | Type | Shares | Avg price | Owned after |
|---|---|---|---|---|---|
| Aug 12, 2026 | Third Rock Ventures V, L.P.10 percent owner | Sale · 2 lots | 147,200 | $50.27 | 6,068,391 |
| Aug 12, 2026 | Ra Capital Management, L.P.director, 10 percent owner: | Sale | 746,500 | $42.50 | 4,777,415 |
| Aug 11, 2026 | Elizabeth Bhattofficer: President and COO | Sale | 25,000 | $44.00 | 174,209 |
| Aug 3, 2026 | Daniel D. Longofficer: SVP, Drug Discovery | Sale · 2 lots | 3,334 | $34.47 | 96,412 |
| Jul 15, 2026 | Elizabeth Bhattofficer: President and COO | Sale | 4,000 | $33.99 | 174,209 |
| Jul 1, 2026 | Daniel D. Longofficer: SVP, Drug Discovery | Sale · 2 lots | 3,333 | $34.36 | 96,412 |
| Jun 29, 2026 | Samira Shaikhlyofficer: Chief People Officer | Sale | 2,178 | $35.18 | 793 |
| Jun 22, 2026 | Daniel D. Longofficer: SVP, Drug Discovery | Sale · 2 lots | 15,000 | $35.51 | 96,412 |
| Jun 12, 2026 | Samira Shaikhlyofficer: Chief People Officer | Sale | 6,250 | $35.08 | 793 |
| Jun 1, 2026 | Samira Shaikhlyofficer: Chief People Officer | Sale · 3 lots | 5,935 | $28.93 | 793 |
CongressHouse and Senate disclosures
Not reported.